Laurie Stellman is a patent professional with extensive experience prosecuting biotechnology and life sciences patent applications spanning a diverse array of therapeutic, diagnostic and platform technologies. Her practice has focused on complex innovations in cell and gene therapy, immuno-oncology, antibody engineering, nucleic acid therapeutics, microbiome technologies and precision medicine, with substantial exposure to emerging biotechnology platforms.
Laurie's experience emphasizes advanced therapeutic modalities, including engineered immune cell therapies, gene editing systems, antibody-based therapeutics, oligonucleotide technologies and microbiome-derived treatments. She also has significant experience with companion diagnostics, biomarker-driven precision medicine, organoid systems and research platform technologies that support drug discovery, translational research and therapeutic development. Her practice centers on the prosecution and strategic management of sophisticated biotechnology patent portfolios across a broad range of life science disciplines.
Representative experience
Therapeutics
-
Small molecule therapeutics, including inhibitors, activators, modulators and molecular mimetics.
-
Gene therapy and delivery technologies, including viral and non-viral delivery systems and lipid nanoparticle formulations.
-
Gene-editing technologies and engineered nucleases.
-
Antibody therapeutics, including monoclonal antibodies, bispecific antibodies, Fab fragments, monobodies and antibody-like scaffolds.
-
Engineered immune cell therapies, including CAR and TCR technologies.
-
Protein and peptide therapeutics.
-
Oligonucleotide-based therapeutics, including ASOs and siRNAs.
-
Cell therapy technologies.
-
Organoid-based therapeutic platforms.
-
Microbiome-based therapeutics.
Diagnostics
-
Companion diagnostic technologies and biomarker-driven precision medicine approaches.
-
Genomic, transcriptomic and nucleic acid-based diagnostics.
-
Protein-based biomarkers and diagnostic signatures.
-
Predictive biomarkers for efficacy and toxicity.
-
Microbiome-derived biomarkers.
Research instruments/tools
-
Cell culture and cell-engineering platforms.
-
In vitro immune-cell differentiation and expansion systems.
-
CAR-T and TCR-T development and manufacturing technologies.
-
Organoid generation and research platforms.
-
Antibody engineering and receptor-engineering technologies.
Digital health
-
Predictive biomarker and signature-based technologies supporting treatment selection and clinical decision-making.
-
Technologies leveraging multi-parameter biological data for precision medicine.
Biomass/industrial biotechnology
-
Microbial and probiotic technologies utilizing living organisms as therapeutic agents.
-
Engineered microbial compositions and microbiome-modulating products.
Awards and recognitions
- Legal 500 US, Recommended Lawyer, Education, The Legal 500, 2025
Education
PhD, Biology, Massachusetts Institute of Technology, 2008
BS, cum laude, Biochemistry, Genetics, Texas A&M University, 2002
Laurie was registered in 2010 with the U.S. Patent and Trademark Office.
Admissions
- US Patent and Trademark Agent
Publications
- *Co-First Authorship, *Friesenhahn LB, *Danielian PS, Faust AM, West JC, Caron AM, Bronson RT, Lees JA; "E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity," Oncogene; 27(51):6561-70, November 20, 2008
- *Co-First Authorship, *Friesenhahn LB, *Courel M, Lees, JA; "E2f6 and Bmi1 cooperate in axial skeletal development," Developmental Dynamics; 237(5):1232-1242, May 2008
- Carvin CD, Dhasarathy A, Friesenhahn LB, Jessen WJ, Kladde MP; "Targeted cytosine methylation for in vivo detection of protein-DNA interactions," Proceedings of the National Academy of Sciences of the United States of America;100(13):7743-8, 2003